Arbutus Biopharma Reacquires Rights to Imdusiran
Arbutus Biopharma Corporation (NASDAQ: ABUS) is back in control of its lead therapeutic candidate, imdusiran, having concluded its partnership with Qilu Pharmaceutical. This marks a pivotal moment in the company's strategy to enhance its focus on the chronic hepatitis B virus (cHBV) treatment pipeline.
Termination of the Qilu Partnership
In a collaborative decision, Arbutus and Qilu Pharmaceutical agreed to end their strategic alliance, established back in 2021, which facilitated the development and commercialization of imdusiran in Greater China. Lindsay Androski, the President and CEO of Arbutus, expressed gratitude towards Qilu for their partnership, recognizing the value it brought over the years. The decision stems from both companies recalibrating their strategies to better align with their core objectives in the biopharmaceutical landscape.
Insights from the Qilu Team
Dr. Weikang Tao, who led the global R&D initiatives at Qilu, remarked on the fruitful collaboration, highlighting the progress made in the development of imdusiran. The decision to conclude the partnership opens new avenues for Arbutus to advance imdusiran independently.
Introducing the New Scientific Advisory Board
With renewed ambitions, Arbutus has also assembled a distinguished Scientific Advisory Board (SAB) comprising leading experts in liver disease treatments. This board will play an integral role in guiding the clinical development of Arbutus’s cHBV programs, ensuring that the company stays at the forefront of research and innovation.
Meet the Advisory Board Members
- Jordan J. Feld, MD, MPH: A leading figure at the University of Toronto, he specializes in viral hepatitis and its complications.
- Edward J. Gane, MBChB, MD: Known for his work on hepatitis C, he is also pushing forward the potential for a cure for hepatitis B.
- Anna Suk-Fong Lok, MD: An esteemed researcher with a wealth of published works on hepatitis B treatment.
- Mark Sulkowski, MD: A veteran in clinical trials, Sulkowski is committed to advancing treatment protocols for viral hepatitis.
- Man-Fung Yuen, MBBS, MD: A prominent researcher from The University of Hong Kong, Yuen’s work is crucial in understanding chronic hepatitis B.
Clinical Achievements of Imdusiran
Arbutus's decision also comes after significant clinical achievements with imdusiran. In two Phase 2a clinical trials, eight out of the patients treated with imdusiran achieved functional cures, indicating the therapy's promising potential. These patients were able to discontinue all existing therapies, showcasing the product's effectiveness.
Understanding Imdusiran
Imdusiran (AB-729) is an RNA interference (RNAi) therapeutic designed to target HBV proteins, which is critical for eliciting an immune response capable of managing the virus. By utilizing a sophisticated delivery method, the treatment has shown to significantly reduce HBsAg levels, providing hope for many living with hepatitis B.
The Importance of Addressing Hepatitis B
Globally, hepatitis B poses a severe health threat, affecting over 250 million individuals and leading to dire complications such as cirrhosis and liver cancer. The urgency to develop effective treatments like imdusiran is underscored by the staggering number of deaths associated with chronic HBV infection.
Arbutus Biopharma's Ongoing Initiatives
In addition to imdusiran, Arbutus is focused on advancing other therapeutics, including an oral PD-1 inhibitor aimed at treating chronic HBV infection. Moreover, the company is actively protecting its intellectual property amidst ongoing litigation involving its proprietary LNP technology.
Frequently Asked Questions
What is imdusiran?
Imdusiran is an RNAi therapeutic designed to reduce HBV viral proteins and antigens, which is crucial for reactivating the immune system.
Why did Arbutus end its partnership with Qilu Pharmaceutical?
The partnership was concluded as both companies aimed to realign their strategic goals, allowing Arbutus to regain full control over imdusiran.
What is the role of the Scientific Advisory Board?
The SAB provides guidance on clinical development strategies for Arbutus’s hepatitis B treatments, ensuring they leverage the expertise of global leaders in the field.
How effective is imdusiran based on clinical trials?
Imdusiran has shown promising results, with eight patients achieving functional cures during Phase 2a trials, demonstrating its potential impact on chronic HBV treatment.
What are Arbutus's other product candidates?
Besides imdusiran, Arbutus is also developing an oral PD-1 inhibitor aimed at enhancing chronic HBV treatment options.
